Search Results - "AstraZeneca"

Malaysia to use AstraZeneca vaccine by Povera, Adib

Get full text
Get full text

Turun padang daftar vaksin AstraZeneca untuk warga emas by Utusan Borneo Sabah

Get full text
Get full text

AstraZeneca Internship: Comparison of Chinese and Indian Contract Research & Manufacturing Organisations by Cheepirishetti, Ashrit

“…AstraZeneca Internship: Comparison of Chinese and Indian Contract Research & Manufacturing Organisations…”
Get full text

Supplier Development at Astra Zeneca, China: Streamlining the Clinical Supply Chain through improved supplier capabilities by Bhardwaj, Saurabh

“…With these issues in the backdrop, we take a closer look at the Clinical Supply Chain at Astra Zeneca, China (AZ). The distribution process is defined and its intricacies are outlined through a detailed analysis of the system. …”
Get full text

How deliberate organizational learning contributes to the attainment of dynamic capabilities? A case Study of AstraZeneca Pharmaceuticals by Muaid, Reem

Get full text

Impact of knowledge / innovation on merger and acquisition success in the pharmaceutical industry: The case of AstraZeneca/Ardea Biosciences and GlaxoSmithKline/Human Genome Sciences by Havard, Victor

“…Through our case study composed of two major mergers (AstraZeneca/Ardea Biosciences and GlaxoSmithKline/Human Genome Sciences) in the context of the pharmaceutical industry, we introduce the variable of knowledge structure to further explain M&A success. …”
Get full text

AN ANALYSIS OF CRO SELECTION PROCESS &RISK ASSESSMENT FOR ASTRAZENECA GENERIC DRUG DEVELOPMENT PROJECT IN CHINA by shetty, shraddha

“…This research work explores the various aspects of the AstraZeneca Generic drug development project (self-development project) highlighting key areas like CRO selection process, project risk assessment & finally analysis of the AstraZeneca Generics drug Business model…”
Get full text

Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply by Persson, Monica S.M., Sarmanova, Aliya, Doherty, Michael, Zhang, Weiya

“…MD reports a grant from AstraZeneca funding a non-drug PI-led study in Nottingham (Sons of Gout study) and honoraria for Advisory boards on osteoarthritis and gout for AstraZeneca, Grunenthal, Mallinckrodt, and Roche, outside the submitted work. …”
Get full text

Pharmaceutical distribution networks in China: analysis of benefits and challenges of entering the Chinese market by Wegner, Jennifer

“…This master dissertation follows an exploratory case study approach based on desktop research as well as information received by an interview with a distribution manager of AstraZeneca in Shanghai. AstraZeneca is a global, vertically integrated bio-pharmaceutical company which entered the Chinese market in 1993. …”
Get full text

Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists by Kindon, Nicholas, Andrews, Glen, Baxter, Andrew, Cheshire, David, Hemsley, Paul, Johnson, Timothy, Liu, Yu-Zhen, McGinnity, Dermot, McHale, Mark, Mete, Antonio, Reuberson, James, Roberts, Bryan, Steele, John, Teobald, Barry, Unitt, John, Vaughan, Deborah, Walters, Iain, Stocks, Michael J.

“…N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 receptor antagonist high throughput screen (HTS) of a sub-set of the AstraZeneca compound bank. As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antagonist candidate drugs.…”
Get full text

Part A: Monoclonal antibody formulations: challenges and developments/ Part B: Characterization of an IgG fab fragment in non-aqueous solvent: Isopropyl Alcohol (IPA) by Shah, Kesha

“…This review will be of great value to the newly reforming NCMH Business Centre based at Sutton Bonington which will act as an advisory and scientific Facility for Biopharma companies such as Astra Zeneca, Arecor, Glaxo Smith Kline, Sanofi and specialising in biopolymer therapeutics and vaccines. …”
Get full text

An examination of the efficacy and background of the Covid-19 vaccine: comparative analysis by Mahmoud, Al-Masaeed, M., Alghawanmeh, A., Al-Singlawi, R., Alsababha, M., Alqudah, A., Alomari, M., Alshawawreh, Rasdi, Irniza

“…Results and findings: The findings indicate that the vaccines analysed, the (i) Pfizer, (ii) Astra Zeneca, (iii) Johnson &, (iv) Moderna, can be categorised into two main levels, namely the mRNA vaccines and the carrier/ virus vector vaccines. …”
Get full text

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer by Dent, R., Lindeman, G., Clemons, M., Wildiers, H., Chan, Arlene, McCarthy, N., Singer, C., Lowe, E., Watkins, C., Carmichael, J.

“…Given the encouraging response rate, alternative scheduling and dosing strategies should be considered (funded by AstraZeneca; ClinicalTrials.gov, NCT00707707). © 2013 Dent et al.; licensee BioMed Central Ltd.…”
Get full text

Inhibition of the p38 MAPK pathway as a strategy to overcome tumour immune suppression in CD1c+ dendritic cells by Chisanga, Chrispin

“…ViewRNA assay was also performed in partnership with AstraZeneca Ltd to understand the potential roles played by CD5, CD209 and Semaphorin 7A (Sema7A) in DC chemotaxis during reduced CCR7 expression. …”
Get full text

Exploring the Potential of Web-Based Communication Media to Improve Non-Financial Reporting Completeness and Comprehensibility by Pandelidis, Theodora Marie

“…This study explores the potential of web-based sustainability reporting methods to improve corporate non-financial reporting completeness and comprehensibility, by analyzing, in detail, the web-based reporting practices of one company, AstraZeneca Pharmaceuticals PLC. Over the last four decades, public enthusiasm for corporate non-financial reporting has both swelled and waned; and the content, format and media for such reporting has evolved. …”
Get full text

Identification of B-cell epitopes for eliciting neutralizing antibodies against the SARS-CoV-2 spike protein through bioinformatics and monoclonal antibody targeting by Lim, Hui Xuan *, Masomian, Malihe *, Kumar, Asqwin Uthaya, MacAry, Paul A., Poh, Chit Laa *

“…Effective COVID-19 vaccines developed by Pfizer-BioNTech, Moderna, and Astra Zeneca have made significant impacts in controlling the COVID-19 burden, especially in reducing the transmission of SARS-CoV-2 and hospitalization incidences. …”
Get full text
Get full text

The use of training in graduate recruitment: Emerging trends and business opportunities by Kennard, Michael James

“…Health: Glaxo Smith Kline, Astra Zeneca, Smith&Nephew 5. Engineering and Industrials: BAE Systems, Rolls-Royce, ICI Twenty five separate subsections divided under the five broad headings were reviewed and rated for each company. …”
Get full text

Kesedaran, pengetahuan dan sikap masyarakat awam terhadap vaksin covid-19 konvensional dan berasaskan bioteknologi moden di Malaysia by Azirul Hanif Sri

“…Justeru, kajian ini bertujuan untuk menilai tahap kesedaran, pengetahuan kendiri dan sikap masyarakat awam mengenai tiga jenis vaksin COVID-19 yang berbeza di Malaysia iaitu vaksin virus tidak aktif seperti Sinovac, vaksin vektor virus seperti AstraZeneca dan vaksin mRNA seperti Pfizer. Satu survei telah dijalankan menggunakan platform tinjauan atas talian ke atas masyarakat awam di Malaysia bermula daripada 19 Jun sehingga 2 Julai 2021. …”
Get full text
Get full text

Molecular characterization of cannabinoids and free fatty acid receptors in human and rat skeletal muscle by Shermado, Fairouz M.

“…Global expression profiling was also carried out on myotubes treated with GPR40 agonists and antagonists obtained from AstraZeneca. No changes in metabolic or insulin signalling genes were observed. …”
Get full text

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease by Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L., Dans, A., Avezum, A., Piegas, L., Parkhomenko, A., Keltai, K., Keltai, M., Sliwa, K., Peters, R., Held, C., Chazova, I., Yusoff, K., Lewis, B., Jansky, P., Khunti, K., Toff, W., Reid, Christopher, Varigos, J., Sanchez-Vallejo, G., McKelvie, R., Pogue, J., Jung, H., Gao, P., Diaz, R., Lonn, E., HOPE-3 Investigators

“…(Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).…”
Get full text